Department of Surgery, Department of Surgical and Perioperative Sciences, Umeå University, By 10A, Norrlands Universitetssjukhus, Umeå, 901 85, Sweden.
Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Clin Exp Metastasis. 2021 Apr;38(2):175-185. doi: 10.1007/s10585-021-10082-2. Epub 2021 Mar 3.
No reliable, non-invasive biomarker of metastatic breast cancer (mBC) exists: circulating CA15-3 (cCA15-3) is the marker mostly used to monitor mBC. Circulating collagen IV (cCOLIV) has been evaluated in other metastatic cancers and has been found to be a promising biomarker. The overarching aim of this study was to evaluate cCOLIV as a potential biomarker in patients with mBC. The first aim was to determine the levels of cCOL IV and cCA15-3 in patients with healthy controls, primary breast cancer (pBC) and mBC. The second aim was to compare levels of cCOLIV and cCA15-3 in patients with different metastatic sites of BC. The third aim was to investigate the prognostic value of cCOLIV and cCA15-3 for mBC patients. The fourth aim was to analyse whether a combination of the two biomarkers was more accurate in detecting mBC than a single marker. Lastly, we investigated the tissue expression levels of COLIV in BC bone metastases (BM) and liver metastases (LM). Plasma levels of cCOLIV and cCA15-3 from healthy controls and patients with pBC and mBC were measured. COLIV expression in tissue from patients with LM and BM was analysed using immunohistochemistry. Clinical and survival data were collected from medical charts. The levels of cCOLIV and cCA15-3 were significantly elevated in mBC patients compared with healthy controls and pBC patients. No differences in cCOLIV and cCA15-3 levels were found based on the metastatic site. High levels of cCOLIV, but not cCA15-3, correlated with poorer survival. cCOLIV alone and the combination of cCA15-3 and cCOLIV were superior to cCA15-3 at detecting mBC. COL IV was highly expressed in the tissue of LM and BM. Our study suggests that cCOLIV is a potential marker to monitor patients with BC.
尚无可靠的、非侵入性的转移性乳腺癌 (mBC) 生物标志物：循环 CA15-3 (cCA15-3) 是最常用于监测 mBC 的标志物。循环型胶原 IV (cCOLIV) 在其他转移性癌症中进行了评估，并被发现是一种很有前途的生物标志物。本研究的总体目标是评估 cCOLIV 作为 mBC 患者的潜在生物标志物。第一个目的是确定健康对照组、原发性乳腺癌 (pBC) 和 mBC 患者的 cCOLIV 和 cCA15-3 水平。第二个目的是比较不同 BC 转移部位患者的 cCOLIV 和 cCA15-3 水平。第三个目的是探讨 cCOLIV 和 cCA15-3 对 mBC 患者的预后价值。第四个目的是分析与单一标志物相比，两种生物标志物的联合是否能更准确地检测 mBC。最后，我们研究了 COLIV 在 BC 骨转移 (BM) 和肝转移 (LM) 组织中的表达水平。测量了健康对照组和 pBC 及 mBC 患者的 cCOLIV 和 cCA15-3 血浆水平。用免疫组织化学法分析了来自 LM 和 BM 患者的组织中 COLIV 的表达。从病历中收集了临床和生存数据。与健康对照组和 pBC 患者相比，mBC 患者的 cCOLIV 和 cCA15-3 水平显著升高。根据转移部位，cCOLIV 和 cCA15-3 水平没有差异。高 cCOLIV 水平，而不是 cCA15-3，与较差的生存相关。cCOLIV 单独检测和 cCA15-3 与 cCOLIV 联合检测均优于 cCA15-3 检测 mBC。COLIV 在 LM 和 BM 的组织中高表达。我们的研究表明 cCOLIV 是一种监测 BC 患者的潜在标志物。
